Epibiologics Appoints Ann Lee-Karlon As Chief Executive Officer And President, Extends Series A Financing To Over $70 Million
Jul 20, 2023•about 2 years ago
Round Type
series a
Investors
GvVivo CapitalPolaris PartnersMubadala CapitalCodon CapitalTaiho VenturesDigitalis Ventures
Description
EpiBiologics, a biotechnology company advancing a next-generation antibody-based protein degradation platform and pipeline for membrane and extracellular drug targets, announced today that Ann Lee-Karlon, Ph.D., will join as Chief Executive Officer, President, and member of the Board of Directors. Dr. Lee-Karlon will focus on expanding EpiBiologics’ proprietary EpiTAC platform, establishing value-driven collaborations, and building the company’s pipeline of bispecific antibody protein degrader therapeutics.
Funding Insights
Based on industry dataVC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers